Case Reports in Dermatology最新文献

筛选
英文 中文
Six Cases of Erythrodermic Pemphigus Foliaceus: A Case Report. 红皮病性天疱疮6例报告。
IF 0.9
Case Reports in Dermatology Pub Date : 2022-09-01 DOI: 10.1159/000525382
Natsumi Norikawa, Shohei Igari, Masato Ishikawa, Tatsuhiko Mori, Tomoko Hiraiwa, Nobuyuki Kikuchi, Yuka Hanami, Toshiyuki Yamamoto
{"title":"Six Cases of Erythrodermic Pemphigus Foliaceus: A Case Report.","authors":"Natsumi Norikawa,&nbsp;Shohei Igari,&nbsp;Masato Ishikawa,&nbsp;Tatsuhiko Mori,&nbsp;Tomoko Hiraiwa,&nbsp;Nobuyuki Kikuchi,&nbsp;Yuka Hanami,&nbsp;Toshiyuki Yamamoto","doi":"10.1159/000525382","DOIUrl":"https://doi.org/10.1159/000525382","url":null,"abstract":"<p><p>Pemphigus foliaceus (PF) is one of the causes of erythroderma; however, to date, there have been relatively few reported cases. We herein describe 6 cases of erythrodermic PF. In all 6 cases, PF was a direct cause of erythroderma because the patients had not undergone any medical treatments and neither had any other skin diseases nor were taking any drugs that typically cause erythroderma. Serum levels of IgE and thymus and activation-regulated chemokine were elevated in 5 of the 6 cases, whereas soluble interleukin-2 receptor and squamous cell carcinoma-related antigen were markedly increased in all cases, suggesting that those markers are strong indicators of skin surface damage. All patients were treated with predonisolon (PSL), of which PSL pulse was added in 4 patients and intravenous immunoglobulin was added in 4 patients. Furthermore, all patients except for one were older adults, among whom 2 cases developed Kaposi's varicelliform eruption, and died, and another 2 patients, respectively, died of gastrointestinal bleeding and sepsis. Kaposi's varicelliform eruption is a complication of erythrodermic PF associated with poor prognosis, and thus caution is necessary when considering the diagnosis. Furthermore, elderly people are more likely to have complications due to PSL, which may result in death. Inappropriate treatment and delay in treatment may cause erythroderma, so early diagnosis and treatment are necessary.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"14 3","pages":"258-263"},"PeriodicalIF":0.9,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/83/cde-0014-0258.PMC9947519.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10794221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A Case of Verrucous Carcinoma Treated by Combination of Radiotherapy and Mohs' Chemosurgery. 放疗联合莫氏化疗治疗疣状癌1例。
IF 0.9
Case Reports in Dermatology Pub Date : 2022-08-31 eCollection Date: 2022-05-01 DOI: 10.1159/000525751
Kozo Kawaguchi, Yuichi Kurihara, Michiaki Akashi, Takeshi Nakahara
{"title":"A Case of Verrucous Carcinoma Treated by Combination of Radiotherapy and Mohs' Chemosurgery.","authors":"Kozo Kawaguchi,&nbsp;Yuichi Kurihara,&nbsp;Michiaki Akashi,&nbsp;Takeshi Nakahara","doi":"10.1159/000525751","DOIUrl":"https://doi.org/10.1159/000525751","url":null,"abstract":"<p><p>Verrucous carcinoma (VC) is a rare subtype of squamous cell carcinoma. VC is histologically a benign tumor, but it grows significantly and eventually forms a huge mass. Many different treatments are known, but the first-line treatment is surgical resection. VC has strong local infiltration and frequently recurs, making its local control very difficult in unresectable cases. We present a rare case of VC that could be treated with combined radiotherapy and Mohs' chemosurgery, as a new option for unresectable VC.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"249-252"},"PeriodicalIF":0.9,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/33/cde-0014-0249.PMC9459585.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33483786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Persistent Facial Blanching after Botulinum Toxin Injection. 注射肉毒毒素后脸部持续变白。
IF 0.9
Case Reports in Dermatology Pub Date : 2022-08-31 eCollection Date: 2022-05-01 DOI: 10.1159/000525937
Fouad Mitri, Katharina Anna Kälber, Alexander H Enk, Ferdinand Toberer
{"title":"Persistent Facial Blanching after Botulinum Toxin Injection.","authors":"Fouad Mitri,&nbsp;Katharina Anna Kälber,&nbsp;Alexander H Enk,&nbsp;Ferdinand Toberer","doi":"10.1159/000525937","DOIUrl":"https://doi.org/10.1159/000525937","url":null,"abstract":"<p><p>We report the case of a 38-year-old male patient who presented with blanching of the face after strenuous exercise or physical exertion. The symptoms regressed in a relaxed state. Three years before presentation, he underwent botulinum toxin injections in the affected areas of the face. Facial blanching is a rare side effect of botulinum toxin injection. The postulated pathophysiology involves different transmitters mainly acetylcholine as well as co-transmitters implicated in vasodilation. Usually, facial blanching resolves shortly after waning of the botulinum toxin. However, in our case, the symptoms persisted for a longer time. Till date, therapy options for post-botulinum facial blanching are lacking, mainly due to the temporary aspect of the disease.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"253-256"},"PeriodicalIF":0.9,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/e3/cde-0014-0253.PMC9459515.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33483787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunochemotherapy - A Missed Opportunity for Metastasized Malignant Melanoma? Reporting a Therapeutic Success with Checkpoint Inhibitor Rechallenge after Cytotoxic Immuno-Priming in a Heavily Pretreated Patient. 免疫化疗-转移性恶性黑色素瘤的一个错过的机会?报告在细胞毒性免疫启动后检查点抑制剂再挑战在重度预处理患者中的治疗成功。
IF 0.9
Case Reports in Dermatology Pub Date : 2022-08-29 eCollection Date: 2022-05-01 DOI: 10.1159/000525153
Til R Kiderlen, Nicola Delmastro, Friedemann Jobst, Maike de Wit
{"title":"Immunochemotherapy - A Missed Opportunity for Metastasized Malignant Melanoma? Reporting a Therapeutic Success with Checkpoint Inhibitor Rechallenge after Cytotoxic Immuno-Priming in a Heavily Pretreated Patient.","authors":"Til R Kiderlen,&nbsp;Nicola Delmastro,&nbsp;Friedemann Jobst,&nbsp;Maike de Wit","doi":"10.1159/000525153","DOIUrl":"https://doi.org/10.1159/000525153","url":null,"abstract":"<p><p>Treatment of metastasized malignant melanoma still has very limited therapeutic options. After exhaustion of immuno-checkpoint inhibition (ICI) and potentially targeted therapy, no promising alternatives are currently available. We report on an 83-year-old patient suffering from disseminated metastatic melanoma who showed an almost complete response to ICI following chemotherapy, after repeated failure of different regimens including two nonresponsive regimens of ICI. The presented outcome suggests a cytotoxic immuno-priming, facilitating a response to prior nonresponsive ICI. As this concept has not been established until now for malignant melanoma, in contrast to multiple other cancer entities, our case report corroborates previous evidence and therefore suggests a new treatment option, which should be researched further.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"243-248"},"PeriodicalIF":0.9,"publicationDate":"2022-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6c/a0/cde-0014-0243.PMC9459574.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33485195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blue Skin, Nail, and Scleral Pigmentation Associated with Minocycline. 二甲胺四环素引起的皮肤、指甲和巩膜色素沉着。
IF 0.9
Case Reports in Dermatology Pub Date : 2022-08-19 eCollection Date: 2022-05-01 DOI: 10.1159/000526067
Jose W Ricardo, Kalee Shah, Kira Minkis, Shari R Lipner
{"title":"Blue Skin, Nail, and Scleral Pigmentation Associated with Minocycline.","authors":"Jose W Ricardo,&nbsp;Kalee Shah,&nbsp;Kira Minkis,&nbsp;Shari R Lipner","doi":"10.1159/000526067","DOIUrl":"https://doi.org/10.1159/000526067","url":null,"abstract":"<p><p>Minocycline, a semisynthetic derivative of tetracycline that is used to treat various infectious and noninfectious conditions, can cause tissue hyperpigmentation. The skin, oral mucosa, sclera, and rarely the nails, can all be affected. The discoloration varies from blue, slate-gray, or brown, and it typically occurs in a dose-dependent fashion. The mechanism of hyperpigmentation, however, remains largely unknown. Herein, we present a case of gray-blue hyperpigmentation of the skin, sclera, and nails after long-term treatment with minocycline for acne.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"239-242"},"PeriodicalIF":0.9,"publicationDate":"2022-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/73/cde-0014-0239.PMC9459581.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33483788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Erythrodermic Psoriasis Managed with Risankizumab. 瑞尚单抗治疗红皮病性银屑病。
IF 0.9
Case Reports in Dermatology Pub Date : 2022-08-19 eCollection Date: 2022-05-01 DOI: 10.1159/000525774
Abdulmajeed Alajlan, Abdulaziz Madani, Tala Ammar Qadoumi, Alhanouf Aljaloud, Mohammed Alessa
{"title":"Erythrodermic Psoriasis Managed with Risankizumab.","authors":"Abdulmajeed Alajlan,&nbsp;Abdulaziz Madani,&nbsp;Tala Ammar Qadoumi,&nbsp;Alhanouf Aljaloud,&nbsp;Mohammed Alessa","doi":"10.1159/000525774","DOIUrl":"https://doi.org/10.1159/000525774","url":null,"abstract":"<p><p>Erythrodermic psoriasis (EP) is a severe, often refractory, variant of psoriasis. Due to the high morbidity and mortality rate associated with EP and other causes of erythroderma, they are often classified as dermatologic emergencies. EP is usually a therapeutic challenge, where topical and conventional systemic therapies have yielded a less than satisfactory result in several patients. Furthermore, there are a limited number of studies evaluating other therapeutic modalities, such as biologic agents, with no clear treatment guidelines. In this case report, we present a patient who was diagnosed as a case of EP and showed an impressive response to risankizumab.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"219-224"},"PeriodicalIF":0.9,"publicationDate":"2022-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/a6/cde-0014-0219.PMC9459644.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Keloid-like Pilomatricoma of the Auricle: A Case Report and Review of Literature. 耳廓瘢痕样毛囊瘤1例报告及文献复习。
IF 0.9
Case Reports in Dermatology Pub Date : 2022-08-19 eCollection Date: 2022-05-01 DOI: 10.1159/000525895
Shinta Trilaksmi Dewi, Hanggoro Tri Rinonce, Kristiana Etnawati, Yohanes Widodo Wirohadidjojo
{"title":"Keloid-like Pilomatricoma of the Auricle: A Case Report and Review of Literature.","authors":"Shinta Trilaksmi Dewi,&nbsp;Hanggoro Tri Rinonce,&nbsp;Kristiana Etnawati,&nbsp;Yohanes Widodo Wirohadidjojo","doi":"10.1159/000525895","DOIUrl":"https://doi.org/10.1159/000525895","url":null,"abstract":"<p><p>Pilomatricoma is a rare benign skin adnexal tumor arising from hair matrix cells. It usually manifests as a firm-to-hard, well-circumscribed, nontender nodule often mistaken as a dermoid cyst. However, its clinical presentation has been reported to mimic keloid. In addition, although it occurs most frequently in the head and neck area, pilomatricoma is rarely reported on the auricle. Herein, we reported a case of pilomatricoma occurring on the posterior part of a 9-year-old girl's auricle. Unlike classic pilomatricoma, the tumor closely resembled a keloid. Nevertheless, histological examination following excision of the tumor revealed a dermal tumor arranged in solid nests consisting of basaloid and ghost cells along with foreign body reaction, calcification, and ossification, confirming the diagnosis of pilomatricoma. The rarity, atypical clinical presentation, and unique location of this tumor contributed to the misdiagnosis of this case. Therefore, we reviewed previous cases of pilomatricoma of the auricle reported in the literature to provide a comprehensive understanding of this rare entity.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"230-238"},"PeriodicalIF":0.9,"publicationDate":"2022-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/18/cde-0014-0230.PMC9459629.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Scleroderma-like Syndrome in the Setting of Pembrolizumab Therapy for Non-Small Cell Lung Cancer: Diagnosis and Dermatologic Management. 派姆单抗治疗非小细胞肺癌的硬皮病样综合征:诊断和皮肤病学管理。
IF 0.9
Case Reports in Dermatology Pub Date : 2022-08-19 eCollection Date: 2022-05-01 DOI: 10.1159/000525887
Davide Fattore, Teresa Battista, Mario De Lucia, Maria Carmela Annunziata, Gabriella Fabbrocini
{"title":"Scleroderma-like Syndrome in the Setting of Pembrolizumab Therapy for Non-Small Cell Lung Cancer: Diagnosis and Dermatologic Management.","authors":"Davide Fattore,&nbsp;Teresa Battista,&nbsp;Mario De Lucia,&nbsp;Maria Carmela Annunziata,&nbsp;Gabriella Fabbrocini","doi":"10.1159/000525887","DOIUrl":"https://doi.org/10.1159/000525887","url":null,"abstract":"<p><p>Immune checkpoint inhibitors play an important role in the treatment of malignancies. ICIs consist of monoclonal antibodies directed against inhibitory immune receptors cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), or programmed cell death-ligand 1 (PD-L1). PD-1 is a receptor expressed by T lymphocytes and has the role of inhibiting their activation. Pembrolizumab is a humanized anti-PD-1 monoclonal antibody. It can improve the immune function of T-cells, which results in significant clinical benefit in the treatment of cancer. Despite its wide use, immunotherapy is associated with a spectrum of side effects known as immune-related adverse events. We present a case of an 82-year-old patient with widespread fibroatrophic skin areas that occurred during a treatment with pembrolizumab for non-small cell lung cancer. Clinical, serological, and histopathological examinations led to the diagnosis of generalized morphea. The patient discontinued pembrolizumab and switched to chemotherapy with pemetrexed and carboplatin. A good therapeutic response was obtained with phototherapy, corticosteroids, and topical calcineurin inhibitors. A focus on the therapeutic management of this skin toxicity in oncological patients is provided.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"225-229"},"PeriodicalIF":0.9,"publicationDate":"2022-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/e0/cde-0014-0225.PMC9459594.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33483785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
UltraPulse Carbon Dioxide Laser Plus Methyl Aminolevulinate-Photodynamic Therapy for the Treatment of Penile Cancer. 超脉冲二氧化碳激光加甲基氨基乙酰丙酸光动力疗法治疗阴茎癌。
IF 0.9
Case Reports in Dermatology Pub Date : 2022-08-05 eCollection Date: 2022-05-01 DOI: 10.1159/000524963
Santo Raffaele Mercuri, Giovanni Paolino, Pina Brianti, Matteo Riccardo Di Nicola, Alberto Martini, Andrea Necchi, Francesco Montorsi
{"title":"UltraPulse Carbon Dioxide Laser Plus Methyl Aminolevulinate-Photodynamic Therapy for the Treatment of Penile Cancer.","authors":"Santo Raffaele Mercuri,&nbsp;Giovanni Paolino,&nbsp;Pina Brianti,&nbsp;Matteo Riccardo Di Nicola,&nbsp;Alberto Martini,&nbsp;Andrea Necchi,&nbsp;Francesco Montorsi","doi":"10.1159/000524963","DOIUrl":"https://doi.org/10.1159/000524963","url":null,"abstract":"<p><p>The treatment of early-stage penile carcinoma is usually represented by wide excision or partial penectomy with or without inguinal lymph node dissection. However, laser ablation of the tumor may have a prominent role as an organ-sparing approach. In this regard, the combination of UltraPulse CO<sub>2</sub> laser and photodynamic therapy (PDT) may be a valid option, especially when surgery is not feasible or refused. UltraPulse CO<sub>2</sub> laser allows for the formation of gentle cutaneous abrasion that destroys the malignant tissue and, at the same time, improving the uptake of methyl aminolevulinate and amplifying the photochemical reaction of PDT in the tumor and surrounding tissue.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"210-213"},"PeriodicalIF":0.9,"publicationDate":"2022-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/fa/cde-0014-0210.PMC9459641.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist. 透皮多巴胺激动剂罗替戈汀贴剂致白皮病。
IF 0.9
Case Reports in Dermatology Pub Date : 2022-08-05 eCollection Date: 2022-05-01 DOI: 10.1159/000525894
Ronan Talty, Goran Micevic, Alice Wang, Christine J Ko, William Damsky
{"title":"Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist.","authors":"Ronan Talty,&nbsp;Goran Micevic,&nbsp;Alice Wang,&nbsp;Christine J Ko,&nbsp;William Damsky","doi":"10.1159/000525894","DOIUrl":"https://doi.org/10.1159/000525894","url":null,"abstract":"<p><p>Leukoderma, or hypomelanosis of the skin, can occur in response to various chemical and pharmacologic substances ranging from topical medications to optic preparations and systemic medications. In this case report, we present a 78-year-old man with a history of restless leg syndrome (RLS) who had been using rotigotine transdermal patches once daily for 1 year and developed leukoderma on the bilateral anterior shoulders in the area of patch application. Histopathologic examination showed an absence of melanocytes at the dermal-epidermal junction confirmed by Melan A stain. While the patient was not bothered by the depigmentation and elected to continue the rotigotine patch for his RLS, this case highlights leukoderma as a potential side effect of dopamine transdermal patches and offers insight into the potential mechanism of hypopigmentation in response to dopamine agonism.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"214-218"},"PeriodicalIF":0.9,"publicationDate":"2022-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/83/cde-0014-0214.PMC9459519.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33483784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信